There is an increasing understanding that chromosomal abnormalities play a major role in the pathogenesis of multiple ... cytogenetic composition will be an integral part of the evaluation of ...

In part 3 of our interview with hematologist-oncologist Don M. Benson, MD, PhD, The Ohio State University Comprehensive ...

Multiple myeloma, historically treated as a single ... Advances in molecular testing, such as cytogenetic analysis of plasma cells, have allowed clinicians to stratify patients based on risk ...

Equecabtagene autoleucel produced “remarkable” responses in patients whose disease progressed after prior BCMA CAR T-cell therapy, researchers reported.

(HealthDay News) — Genetic tests can show which patients with the blood cancer multiple myeloma should respond to targeted ...

Background. A 59-year-old woman presented to the emergency department with a left rib fracture and was diagnosed with IgA multiple myeloma. The patient underwent autologous bone-marrow ...

“When we think about how far we’ve come in multiple myeloma, we’re so excited about the potential power of CAR T-cell therapy ...

In a discussion with Peers & Perspectives in Oncology, fellowship program director Marc J. Braunstein, MD, PhD, FACP, and ...

Treated with a dexamethasone-sparing regimen, frail older adult patients with newly diagnosed multiple myeloma (MM ... cancer stage, cytogenetics, and creatinine clearance; however, those with ...

A significant overall survival (OS) benefit with belantamab mafodotin (belantamab; Blenrep) in a phase III trial of relapsed ...

During a Case-Based Roundtable® event, Hira Shaikh, MD, and participants discussed how they would treat a patient with ...

announce that groundbreaking data on the Prognostic Value of the SKY92 Classifier over High-Risk Cytogenetic Aberrations in Multiple Myeloma will be presented during the upcoming American Society ...